Simple markers can distinguish Takotsubo cardiomyopathy from ST segment elevation myocardial infarction
Monika Budnik1, Janusz Kochanowski1, Radoslaw Piatkowski1
11st Department of Cardiology, Medical University of Warsaw, 1a Banacha Street, 02-097 Warsaw, Poland.
Insights
New cardiac biomarker ratios, including NT-proBNP/TnI, can help differentiate Takotsubo cardiomyopathy (TTC) from ST-segment elevation myocardial infarction (STEMI) early. The NT-proBNP/TnI ratio shows the most promise for accurate diagnosis.
Area of Science:
- Cardiology
- Biomarker Discovery
- Diagnostic Tools
Background:
- Takotsubo cardiomyopathy (TTC) presents similarly to acute myocardial infarction, necessitating reliable diagnostic markers.
- Current diagnostic approaches lack a specific biomarker for early TTC identification and differentiation from ST-segment elevation myocardial infarction (STEMI).
- This study investigates readily available hospital markers for TTC diagnosis.
Purpose of the Study:
- To identify simple, accessible biomarkers for the early diagnosis of Takotsubo cardiomyopathy (TTC).
- To differentiate TTC from ST-segment elevation myocardial infarction (STEMI) using cardiac biomarker ratios.
- To evaluate the diagnostic accuracy of NT-proBNP, TnI, CKMB mass, and their ratios.
Main Methods:
- A comparative study involving 66 patients with TTC and 66 patients with STEMI.
- Measurement of cardiac biomarkers (NT-proBNP, TnI, CKMB mass) within 12 hours of admission.
- Analysis of demographic, clinical, and echocardiographic data alongside biomarker levels.
Main Results:
- Elevated NT-proBNP levels were observed in TTC patients compared to STEMI patients (4702 pg/ml vs 2138 pg/ml).
- STEMI patients showed higher concentrations of TnI and CKMB mass than TTC patients.
- Significantly higher NT-proBNP/TnI, NT-proBNP/CKMB mass, and NT-proBNP/EF ratios were found in the TTC group compared to the STEMI group (p<0.001).
Conclusions:
- NT-proBNP/TnI, NT-proBNP/CKMB mass, and NT-proBNP/EF ratios are effective in distinguishing TTC from STEMI in the early stages.
- The NT-proBNP/TnI ratio demonstrated the highest accuracy for differentiating TTC from STEMI.
- These biomarker ratios offer a valuable tool for early diagnosis and management of cardiac emergencies.
Background:
Takotsubo cardiomyopathy (TTC) is a clinical condition mimicking acute myocardial infarction. A specific biomarker for TTC screening is required, but until now, no single biomarker has been established for the early diagnosis of TTC and differentiation from ST-segment elevation myocardial infarction (STEMI). In our study we focused on the simple markers that are available in every hospital.
Methods:
In 66 consecutive patients (pts) who were hospitalized with TTC and 66 pts with STEMI, cardiac biomarkers, such as NT-proBNP, TnI, CK and CKMB mass were determined during 12h from admission and compared with demographic, clinical and echocardiographic findings.
Results:
The concentration of NTproBNP was greater in pts with TTC than STEMI (4702pg/ml vs 2138pg/ml). The concentration of TnI and CKMB mass was greater in the STEMI group than in the TTC group (TnI: 2.1ng/ml and CK MB mass: 9.5ng/ml in pts with TTC vs TnI: 19ng/ml and CK MB mass: 73.3ng/ml in pts with STEMI). The NTproBNP/TnI ratio and NTproBNP/CKMB mass ratio were, respectively, 2235.2 and 678.2 in pts with TTC and 81.6 and 27.5 in pts with STEMI (p<0.001). Moreover, the NTproBNP/EF ratio was also statistically significant (110.4 in TTC group and 39.4 in STEMI group).
Conclusions:
NTproBNP/TnI, NTproBNP/CKMB mass and NTproBNP/EF ratios can distinguish TTC from STEMI at an early stadium. The most accurate marker is the NTproBNP/TnI ratio.
Related Concept Videos
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:25Cardiomyopathy I: Introduction and Classification
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests